Procept BioRobotics

PROCEPT BioRobotics is a mission-driven medical device company dedicated to transforming BPH treatment globally through its innovative Aquablation therapy platform. Its core achievement is the FDA-cleared HYDROS Robotic System, which combines real-time imaging, robotic precision, and heat-free waterjet ablation to offer superior safety and efficacy, particularly for larger prostates, as demonstrated in landmark clinical trials. The company's strategy focuses on aggressive commercial expansion, leveraging a direct sales force to drive system placements and procedure adoption, thereby capturing a significant share of the large and underserved BPH surgical market.

The HYDROS Robotic System integrates real-time multi-planar ultrasound imaging, AI-powered treatment planning software, and a robotic arm that delivers heat-free waterjet energy (Aquablation) for precise and tissue-selective ablation of the prostate.

PROCEPT competes with traditional TURP, laser therapies (HoLEP, PVP), and minimally invasive devices (UroLift, Rezūm). Its primary competitive advantages are its unique robotic waterjet technology, Level 1 clinical evidence demonstrating superior safety, and efficacy in large prostates—a segment poorly served by alternatives.